iko-shutterstock-com
iko / Shutterstock.com
20 August 2015Americas

Omeros to sue Par over generic Omidria application

Biopharmaceutical company Omeros has said that it plans to sue Par Pharmaceutical over its attempt to market a generic version of Omeros's eye treatment drug Omidria (phenylephrine and ketorolac injection).

On Monday, August 17, Omeros said filing a lawsuit is a standard procedure for a company in the life sciences industry that faces potential generic competition for one of its drugs.

Last month, Par submitted an Abbreviated New Drug Application, to the US Food and Drug Administration seeking approval to market a generic version of Omidria.

Gregory Demopulos, chief executive of Omeros, said that Par’s ANDA confirmed the company’s belief in the drug’s market potential.

“We are confident in the strength of our product's broad patent estate. We have engaged one of the premier biotechnology patent litigation teams in the country [law firm Covington & Burling] to pursue aggressively our case against Par, so I do not anticipate this effort becoming a distraction,” Demopulos said.

He added: “We remain focused on continuing to build on our successful launch of Omidria and on increasing the product's market uptake.”

Omidria is given to patients during cataract surgery. The drug maintains the size of pupils by preventing intraoperative miosis and therefore reduces postoperative ocular pain.

Last week, Omeros reported that Omidria had generated  just over $3 million in sales in the second quarter of 2015.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
7 September 2015   Biopharmaceutical company Omeros has hit its competitor Par Pharmaceutical with two lawsuits at US district courts over the drug company’s attempt to market a generic version of its Omidria product.

More on this story

Americas
7 September 2015   Biopharmaceutical company Omeros has hit its competitor Par Pharmaceutical with two lawsuits at US district courts over the drug company’s attempt to market a generic version of its Omidria product.

More on this story

Americas
7 September 2015   Biopharmaceutical company Omeros has hit its competitor Par Pharmaceutical with two lawsuits at US district courts over the drug company’s attempt to market a generic version of its Omidria product.